3DforScience published 3-year data on a new therapy for retinitis pigmentosa from researchers last month.
Public source
Publisher name
Public post
We often talk about the future of eye care as if it’s years away. But for some patients with advanced retinal disease, that future is already here. Let me show you how.…
Company
3DforScience
Global Scientific Communications
- Industry
- Advertising Services
- Location
- Madrid, ES
- Company size
- 11–50 employees
About 3DforScience
Transform your scientific communication with 3DforScience, where innovation meets imagination! We're not just another scientific communication company; we're pioneers in transforming complex ideas into captivating visuals that leave a lasting impact. Our mission is to rebuild pharmaceutical, biotechnology, and healthcare companies' communication through the power of 3D animations, omnichannel modular content, training materials, virtual reality, and interactive experiences. Contact : Phones: +34 900 983 476 +1 844-933-5034 Mail: info@3dforscience.com https://3dforscience.com/
See moreLatest activity
Latest activity from 3DforScience
5 signals
Products & Services
3DforScience created a scientific animation for Mölnlycke Health Care to explain how Avance Solo Adapt works under negative pressure wound therapy.
Products & Services
3DforScience animated how Therasphere makes radiation possible through Y-90 glass microspheres delivered via a catheter through the femoral artery to fight a liver tumor.
Research & Knowledge
3DforScience published a full article detailing how the team of scientists, designers, and animators translated complex biological processes into clear, accessible visual stories for dermo-aesthetics.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Underscore Marketing
Underscore Marketing published a recent CNBC report featuring Jacalyn Lee, whose daughter Isla was diagnosed with an ultra-rare genetic condition called DAND.
Research & Knowledge
Foundation Fighting Blindness
Foundation Fighting Blindness highlighted that LUXTURNA® is the first FDA-approved gene therapy for an inherited disease treating LCA2 caused by mutations in the RPE65 gene.
Research & Knowledge
Imagine Eyes
Imagine Eyes published findings from the KEYS natural history study at Kobe City Eye Hospital, which involved two years of research on EYS-associated retinitis pigmentosa using adaptive optics retinal cameras.
Research & Knowledge
Cleveland Sight Center
Cleveland Sight Center is conducting a trial to see if cellular-rejuvenation therapy will reverse age-related diseases like glaucoma after 30 years of research and hard work.
Research & Knowledge
The Smith-Kettlewell Eye Research Institute